Faropenem is an orally active beta-lactam antibiotic belonging to the penem group. It is resistant to some forms of extended-spectrum beta-lactamase. It is available for oral use.
Faropenem is an orally active beta-lactam antibiotic belonging to the penem group. It is resistant to some forms of extended-spectrum beta-lactamase. It is available for oral use.
==Forms== Faropenem was developed by Daiichi Asubio Pharma, which markets it in two forms. The sodium salt faropenem sodium, available under the trade name Farom, has been marketed in Japan since 1997. () The sodium salt faropenem sodium, available under the trade name Orfanem, has been marketed in Bangladesh by Incepta Pharmaceuticals Ltd. The prodrug form faropenem medoxomil (also known as faropenem daloxate) has been licensed from Daiichi Asubio Pharma by Replidyne, which plans to market it in conjunction with Forest Pharmaceuticals. The trade name proposed for the product was Orapem, but company officials recently announced this name was rejected by the FDA.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).